Management of Antiplatelet Therapy Before Thoracentesis

Introduction to Bleeding Risk Management

The American College of Chest Physicians recommends interrupting clopidogrel for 5 days prior to surgery or procedures with major bleeding risk 1
Thoracentesis is considered a high-risk procedure for bleeding complications when patients are on antiplatelet therapy 2

High thrombotic risk patients, such as those with drug-eluting coronary stents placed within 12 months, bare metal stents within 1 month, recent acute coronary syndrome, or prosthetic heart valve and atrial fibrillation, require cardiology consultation 3, 2, 4
Low thrombotic risk patients, such as those with ischemic heart disease without coronary stents, stents placed >12 months ago, peripheral vascular disease, or atrial fibrillation without valvular disease, are safer to discontinue clopidogrel 3, 2, 4

For low thrombotic risk patients, discontinue clopidogrel 5 days before thoracentesis and resume within 24-48 hours after procedure if hemostasis is achieved 1, 3, 4
For high thrombotic risk patients, consult cardiology before discontinuing clopidogrel, consider continuing aspirin if on dual antiplatelet therapy, and discuss risks and benefits with the patient if procedure cannot be delayed 2, 3

Emerging evidence on the safety of continuing clopidogrel during thoracentesis is limited by small sample sizes, mostly retrospective designs, variable definitions of bleeding complications, and potential selection bias in patient enrollment 3, 4